Adagene News

Latest Adagene Stock News & ADAG Headlines

Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

6 days ago | globenewswire.com

Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890 in Patients with Microsatellite Stable Colorectal Cancer

18 days ago | globenewswire.com

Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

19 days ago | globenewswire.com

Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer

21 days ago | marketbeat.com

Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts

a month ago | defenseworld.net

Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts

a month ago | marketbeat.com

Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference

a month ago | globenewswire.com

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

2 months ago | globenewswire.com

Insider Buying: Adagene (NASDAQ:ADAG) CEO Acquires $63,913.50 in Stock

2 months ago | defenseworld.net

Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago | seekingalpha.com

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

Market Closed

ADAG

Adagene

$ 1.71

-14.50%

Last 24H

Trading with leverage comes with a high risk and may not be suitable for everyone.

Portfolio

Updated a day ago

Top

Gainers

Losers

Symbol

Last Price

24H CNG

Adagene News

Latest Adagene Stock News & ADAG Headlines

Download App

People Also Watch

Explore our Tools